This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Low Malignant Potential Tumors Treatment
Definitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define ovarian low malignant potential tumors; the FIGO system is most commonly used.[1,2]Table 1. Carcinoma of the OvaryaStagea Adapted from FIGO Committee on Gynecologic Oncology.b In order to evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or IIc, it would be of value to know if rupture of the capsule was spontaneous, or caused by the surgeon; and if the source of malignant cells detected was peritoneal washings, or ascites.IGrowth limited to the ovaries.IaGrowth limited to one ovary; no ascites present containing malignant cells. No tumor on the external surface; capsule intact.IbGrowth limited to both ovaries; no ascites present containing malignant cells. No tumor on the external surfaces; capsules intact.IcbTumor either stage Ia or Ib, but with tumor on surface of one
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Stage I Ovarian Germ Cell TumorsTreatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor. Treatment of dysgerminoma may include the following: Unilateral salpingo-oophorectomy with or without lymphangiography or CT scan.Unilateral salpingo-oophorectomy followed by observation.Unilateral salpingo-oophorectomy followed by radiation therapy.Unilateral salpingo-oophorectomy followed by chemotherapy.Treatment of other ovarian germ cell tumors may be either: unilateral salpingo-oophorectomy followed by careful observation; orunilateral salpingo-oophorectomy, sometimes followed by combination chemotherapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting
Avoiding risk factors and increasing protective factors may help prevent cancer.Avoiding cancer risk factors may help prevent certain cancers. Risk factors include smoking, being overweight, and not getting enough exercise. Increasing protective factors such as quitting smoking, eating a healthy diet, and exercising may also help prevent some cancers. Talk to your doctor or other health care professional about how you might lower your risk of cancer.The following risk factors may increase the risk of ovarian cancer:Family history of ovarian cancerA woman whose mother or sister had ovarian cancer has an increased risk of ovarian cancer. A woman with two or more relatives with ovarian cancer also has an increased risk of ovarian cancer. Inherited riskThe risk of ovarian cancer is increased in women who have inherited certain changes in the following genes:BRCA1 or BRCA2 genes.Genes that are linked to hereditary nonpolyposis colorectal cancer (HNPCC; Lynch syndrome).Hormone replacement
DysgerminomasStandard treatment options:Total abdominal hysterectomy and bilateral salpingo-oophorectomy.Unilateral salpingo-oophorectomy with adjuvant chemotherapy.For patients with stage III dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy are recommended with removal of as much gross tumor as can be done safely without resection of portions of the urinary tract or large segments of the small or large bowel. Patients who want to preserve fertility may be treated with unilateral salpingo-oophorectomy if chemotherapy is to be employed.[1,2,3,4,5] (Refer to the PDQ summary on Sexuality and Reproductive Issues for more information on fertility.)Combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP) can cure the majority of such patients. In a report of results from two Gynecologic Oncology Group (GOG) trials, 19 of 20 patients with incompletely resected tumors who were treated with BEP or cisplatin, vinblastine, and bleomycin (PVB) were
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
For more information from the National Cancer Institute about ovarian epithelial cancer, see the following:Ovarian Cancer Home PageWhat You Need to Know About™ Ovarian CancerOvarian Cancer PreventionOvarian Cancer ScreeningUnusual Cancers of ChildhoodDrugs Approved for Ovarian CancerUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies)Targeted Cancer TherapiesBRCA1 and BRCA2: Cancer Risk and Genetic TestingGenetic Testing for Hereditary Cancer SyndromesFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.General Information About Ovarian Epithelial Cancer Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Screening